Kurse um 15 Minuten verzögert
Die Reihe ist auf die aktuelle Aktienzahl nach Splits umgerechnet; Dividenden sind nicht im Kurs enthalten
| Datum | Eröffnung | Hoch | Tief | Schluss | Volumen, Stück |
|---|---|---|---|---|---|
| 15. September 2026 | 272,27 | 276,09 | 269,93 | 272,88 | 983.700 |
| 14. September 2026 | 278,27 | 279,64 | 267,27 | 273,11 | 1 Mio. |
| 11. September 2026 | 276,01 | 280,40 | 275,63 | 278,26 | 767.600 |
| 10. September 2026 | 275,38 | 275,88 |
Auf Basis der Berichte bis 31. Dezember 2025
Charles River supports preclinical research — laboratory animals, disease models and drug safety testing.
Before a drug reaches humans it is tested for safety, and the regulator requires specific procedures. The company supplies the research animals, the laboratories and the specialists — a stage a developer finds cheaper to outsource than to maintain.
Demand depends on how many programmes the industry is starting, and that in turn on the availability of money at biotech start-ups and on large pharmaceutical budgets. A separate factor is regulators gradually accepting alternative methods in place of animal testing. Risks: shrinking research budgets and ethical pressure. The company pays no dividend.
Adresse:251 BALLARDVALE ST, WILMINGTON, MA, 01887, US
| 112 Mio. |
| BIAFbioAffinity Technologies, Inc. | 8,36 | +5.590,70 % | 52 Mio. |
| ABSIAbsci Corporation | 9,42 | +1.715,40 % | 24 Mio. |
| OABIOmniAb, Inc. | 4,41 | +137,90 % | 9 Mio. |
| NRCNRC Health | 20,89 | −528,30 % | 3 Mio. |
| 272,06 |
| 273,00 |
| 764.700 |
| 09. September 2026 | 278,54 | 280,75 | 275,00 | 278,35 | 789.200 |
| 08. September 2026 | 285,60 | 285,94 | 280,16 | 280,76 | 729.100 |
| 04. September 2026 | 288,29 | 291,69 | 285,34 | 288,50 | 738.900 |
| 03. September 2026 | 294,21 | 295,77 | 285,56 | 293,35 | 646.300 |
| 02. September 2026 | 285,49 | 292,55 | 282,56 | 291,76 | 606.500 |
| 01. September 2026 | 289,26 | 290,53 | 280,91 | 282,34 | 705.700 |
| 31. August 2026 | 285,91 | 291,41 | 284,34 | 288,24 | 1 Mio. |
| 28. August 2026 | 291,66 | 294,89 | 289,60 | 291,50 | 659.800 |
| 27. August 2026 | 297,01 | 303,31 | 295,93 | 296,41 | 901.300 |
| 26. August 2026 | 293,17 | 299,53 | 290,01 | 295,10 | 1 Mio. |
| 25. August 2026 | 299,93 | 300,59 | 295,36 | 297,64 | 883.500 |
| 24. August 2026 | 297,63 | 299,02 | 290,73 | 298,58 | 786.100 |
| 21. August 2026 | 291,78 | 298,18 | 289,07 | 295,19 | 887.500 |
| 20. August 2026 | 285,72 | 299,32 | 281,73 | 291,45 | 1 Mio. |
| 19. August 2026 | 284,22 | 294,56 | 280,68 | 290,00 | 987.400 |
| 18. August 2026 | 286,40 | 289,60 | 279,06 | 279,19 | 703.700 |